[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100659512":3},{"organization":4,"outcomesModule":7,"designInfo":41,"detailedDescription":47,"studyPopulation":40,"armGroups":48,"interventions":60,"overallOfficials":40,"centralContacts":69,"locations":79,"responsibleParty":93,"collaborators":40,"id":97,"slug":98,"hasResults":99,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":40,"eligibilityCriteria":102,"healthyVolunteers":99,"sex":103,"minAge":104,"maxAge":40,"enrollmentInfo":105,"targetDuration":40,"studyType":108,"phases":109,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":116,"whyStopped":40,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},{"fullName":5,"class":6},"Assiut University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":21,"otherOutcomes":40},[9,13,17],{"measure":10,"description":11,"timeFrame":12},"Change in Pain Intensity from Baseline as Assessed by the Numerical Rating Scale (NRS)","Pain intensity assessed using the 11-point Numerical Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst pain imaginable). Higher scores indicate worse pain. Comparison based on mean change from baseline between the EUS-guided and percutaneous groups.","Time Frame: Baseline, 6 weeks, and 12 weeks post-procedure",{"measure":14,"description":15,"timeFrame":16},"Change in Pain Intensity from Baseline as Assessed by the Visual Analog Scale (VAS)","Pain intensity assessed using a 100-mm Visual Analog Scale (VAS), ranging from 0 mm (no pain) to 100 mm (worst pain imaginable). Higher scores indicate worse pain. Comparison based on mean change from baseline between groups.","Baseline, 6 weeks, and 12 weeks post-procedure",{"measure":18,"description":19,"timeFrame":20},"Incidence of Procedure-Related Adverse Events","Number and percentage of participants experiencing procedure-related adverse events (e.g., bleeding, infection, hypotension, diarrhea, retroperitoneal hematoma), graded according to CTCAE v5.0 and compared between the EUS-guided and percutaneous groups","Through 12 weeks post-procedure",[22,26,30,33,37],{"measure":23,"description":24,"timeFrame":25},"Duration of Pain Relief","Time from procedure to loss of at least 50% reduction in pain score (NRS\u002FVAS) from baseline, reported in weeks.","Up to 12 weeks post-procedure",{"measure":27,"description":28,"timeFrame":29},"Patient Satisfaction with Treatment","Assessed using a 5-point Likert Scale, ranging from 1 (very dissatisfied) to 5 (very satisfied). Higher scores indicate greater satisfaction.","6 weeks and 12 weeks post-procedure",{"measure":31,"description":32,"timeFrame":29},"Patient Global Impression of Change (PGIC)","Assessed using the Patient Global Impression of Change scale, a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).",{"measure":34,"description":35,"timeFrame":36},"Functional Disability as Assessed by the Oswestry Disability Index (ODI)","Functional disability assessed using the Oswestry Disability Index, scored as a percentage from 0% to 100%. Higher scores indicate greater disability.","Baseline, 6 weeks, and 12 weeks",{"measure":38,"description":39,"timeFrame":36},"Change in Quality of Life as Assessed by the EQ-5D-5L","Health-related quality of life assessed using the EQ-5D-5L questionnaire (5 dimensions: mobility, self-care, usual activities, pain\u002Fdiscomfort, anxiety\u002Fdepression; 5 severity levels each), together with the EQ Visual Analog Scale (0-100, higher = better self-rated health).",null,{"allocation":42,"interventionModel":43,"interventionModelDescription":40,"primaryPurpose":44,"observationalModel":40,"timePerspective":40,"maskingInfo":45},"RANDOMIZED","PARALLEL","SUPPORTIVE_CARE",{"masking":46,"maskingDescription":40,"whoMasked":40},"NONE","Primary objective To compare the efficacy and safety of endoscopic ultrasound (EUS)-guided versus percutaneous (ultrasound-guided) celiac plexus block in controlling pain in patients with upper gastrointestinal malignancies (pancreatic cancer and hepatocellular carcinoma) and chronic pancreatitis.\n\nSecondary Objectives\n\n* To compare the degree and duration of pain relief achieved by EUS-guided versus percutaneous celiac plexus block, assessed by a validated pain scale, over a 6-month follow-up period.\n* To compare the impact of each technique on health-related quality of life, using the EORTC QLQ-C30 (all patients) with the PAN26 module (pancreatic cancer patients only).",[49,55],{"label":50,"type":51,"description":52,"interventionNames":53},"EUS guided celiac plexus block","ACTIVE_COMPARATOR","Participants receive celiac plexus block under endoscopic ultrasound guidance.",[54],"Procedure: Endoscopic Ultrasound-Guided Celiac Plexus Block",{"label":56,"type":51,"description":57,"interventionNames":58},"Percutaneous Celiac Plexus Block","Participants receive celiac plexus block via percutaneous approach.",[59],"Procedure: Percutaneous Celiac Plexus Block",[61,66],{"type":62,"name":63,"description":64,"armGroupLabels":65,"otherNames":40},"PROCEDURE","Endoscopic Ultrasound-Guided Celiac Plexus Block","Celiac plexus block via endoscopic ultrasound",[50],{"type":62,"name":56,"description":67,"armGroupLabels":68,"otherNames":40},"Celiac plexus block via percutaneous route image guided",[56],[70,75],{"name":71,"role":72,"phone":73,"phoneExt":40,"email":74},"Ahmed Elhussiny Salah, Assistant lecturer","CONTACT","+201157104164","ahmedelhosieny298@gmail.com",{"name":76,"role":72,"phone":77,"phoneExt":40,"email":78},"Mohamed Abdelghani Abdelhamid, Lecturer","+201015551669","Moh7111@aun.edu.eg",[80],{"facility":5,"status":40,"city":81,"state":40,"zip":40,"country":82,"countryCode":83,"cosmosGeoPoint":84,"geoPoint":89,"contacts":90},"Asyut","Egypt","EG",{"type":85,"coordinates":86},"Point",[87,88],31.18368,27.18096,{"lat":88,"lon":87},[91],{"name":92,"role":72,"phone":40,"phoneExt":40,"email":40},"Assiut University, faculty of medicine",{"type":94,"investigatorFullName":95,"investigatorTitle":96,"investigatorAffiliation":5,"oldNameTitle":40,"oldOrganization":40},"PRINCIPAL_INVESTIGATOR","Ahmed Elhussiny Salah Mahmoud","assistant lecturer","100659512","endoscopic-ultrasound-guided-versus-percutaneous-celiac-plexus-block-in-patients-with-intractable-upper-abdominal-pain-100659512",false,"NCT07865286","Endoscopic Ultrasound Guided Versus Percutaneous Celiac Plexus Block in Patients With Intractable Upper Abdominal Pain","Inclusion Criteria:\n\n* 1\\. Age: ≥ 18 years 2. Diagnosis: Histologically or cytologically confirmed upper abdominal malignancy, including:\n* Pancreatic cancer\n* Gastric cancer\n* Duodenal cancer\n* Biliary tract cancer (cholangiocarcinoma, gallbladder cancer)\n* Hepatocellular carcinoma (HCC) 3. Chronic Abdominal Pain: Intractable upper abdominal pain attributed to the underlying disease 4. Pain Severity: Visual Analogue Scale (VAS) score ≥ 4\u002F10 on at least 50% of days in the preceding 4 weeks, despite optimal medical therapy 5. Stable Analgesic Regimen: For ≥ 4 weeks prior to enrollment 6. Performance Status: ECOG 0-2 7. Informed Consent: Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n1\\. Age: \\\u003C 18 years 2. Coagulopathy: INR \\> 1.5 or platelet count \\\u003C 50,000\u002FμL, or use of anticoagulants that cannot be safely withheld per procedure guidelines 3. Allergy: Known allergy to local anesthetics or corticosteroids 4. Pregnancy: Intrauterine pregnancy or breastfeeding 5. Altered Anatomy: Anatomical variation, prior surgery, or interposed structures precluding safe performance of either procedure.\n\n\\-","ALL","18 Years",{"count":106,"type":107},100,"ESTIMATED","INTERVENTIONAL",[110],"NA","Upper abdominal pain is a common and often debilitating symptom in patients with pancreatic cancer and chronic pancreatitis, and is frequently under-treated by standard opioid therapy despite dose escalation and associated side effects \\[1\\]. In chronic pancreatitis, abdominal pain is present in the great majority of patients and is often the dominant factor driving impaired quality of life, with celiac plexus block considered an interventional option for temporary relief \\[2\\]. Pain arising from both malignant and benign upper abdominal pathology is transmitted through the celiac plexus, an autonomic plexus located in the retroperitoneum at the root of the celiac trunk, making it a rational target for pain-relieving intervention in either disease process \\[3\\]. Two image-guided approaches have been developed to interrupt this pathway: the percutaneous route, performed under fluoroscopic or CT guidance \\[5\\], and the endoscopic ultrasound-guided route, performed transgastrically at the time of upper endoscopy, which allows direct visualization of the celiac plexus and may reduce the risk of injury to adjacent structures compared with the percutaneous approach \\[3,9\\]. Neurolytic celiac plexus block has been shown to improve pain relief in patients with unresectable pancreatic cancer \\[6\\], while EUS-guided celiac plexus block has similarly demonstrated efficacy in relieving pain associated with chronic pancreatitis \\[7\\]. Direct comparisons between the two approaches, however, remain limited: existing trials and meta-analyses in both chronic pancreatitis \\[2,8\\] and pancreatic cancer \\[4,9\\] show inconsistent superiority of one technique over the other, and the choice between them in practice has historically relied more on institutional expertise than on robust head-to-head evidence",[113],"Celiac Plexus Block",[115],"celiac plexus block","NOT_YET_RECRUITING","2026-10-03",{"date":119,"type":120},"2026-10-08","ACTUAL",{"date":122,"type":107},"2026-12-01",{"date":124,"type":107},"2029-06-30",{"name":5,"class":6},1]